TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...

Q2 2025 Earnings Call Transcript July 31, 2025 Operator: Good afternoon, and welcome to TransMedics Second Quarter 2025 ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present ...

TransMedics posted strong Q2 results with solid growth and improving margins, while heart and lung programs offer key upside.

Medical experts conduct several tests to assess the health of the donor’s organs and other critical health details ...

July 31, 2025) Findings from St. Jude Children's Research Hospital demonstrate that virtual memory T cells, a specialized group of ...

Organ transplants not only save lives, they transform them. For our vital organs like hearts and lungs the impact of a ...

TransMedics Group (NASDAQ:TMDX) beat GAAP revenue and earnings estimates for the second quarter of 2025, with GAAP revenue up 38% year over year. GAAP EPS more than doubled versus analyst forecasts, ...

A 66-year-old Guatemalan, with end-stage lung failure and dependent on oxygen 24 hours a day, found a new lease of life after ...

Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

Researchers have enhanced cisplatin’s efficacy in advanced NSCLC by transplanting functional mitochondria from cardiomyocytes ...

NeuroScientific Biopharmaceuticals is transferring its patented tech to one of Australia’s most experienced stem cell ...